---
type: "Topics"
locale: "en"
url: "https://longbridge.com/en/topics/42648881.md"
description: "$Q32 Bio(QTTB.US) surged +90% in a single day. The Phase 2a primary endpoint for its alopecia areata drug, bempikibart, was met, with SALT-20 response rates achieved and sustained durability after treatment cessation—this is how direct clinical readouts are for small-cap Biotechs; meeting endpoints triggers a revaluation. On the cash front, a $55 million private placement was just completed in May, but to truly advance to Phase 3, the funding gap is an unavoidable hurdle ahead. The numbers themselves are the news; if you're chasing, you have to acknowledge this is a repricing following a binary event."
datetime: "2026-07-14T10:29:12.000Z"
locales:
  - [en](https://longbridge.com/en/topics/42648881.md)
  - [zh-CN](https://longbridge.com/zh-CN/topics/42648881.md)
  - [zh-HK](https://longbridge.com/zh-HK/topics/42648881.md)
author: "[本职喵星人](https://longbridge.com/en/profiles/27713076.md)"
generator: "portal-rs"
---

# $Q32 Bio(QTTB.US) surged +90% in a single day. The…


### Related Stocks

- [QTTB.US](https://longbridge.com/en/quote/QTTB.US.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**